Compare Tapestry, Inc. (TPR) vs 10X Genomics Inc (TXG) Price & Performance

TPR trades at $115.82, up 2.14% today, with strong analyst support (73% buy ratings) and a $174.64 consensus price target suggesting 51% upside. The stock shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. However, technical indicators signal bearish momentum, and 2025 net income declined significantly to $183M from prior years above $800M. Recent news highlights Coach's momentum and international growth in China and Europe.

The investment case balances strong brand performance and analyst optimism against execution risks and valuation concerns. Upside potential exists from earnings beats and international expansion, but investors face headwinds from Kate Spade performance issues, tariff pressures, and the stock's current bearish technical trend. The significant gap between current price and analyst targets presents opportunity if fundamental improvements materialize.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.